Rheumatology real-world evidence studies are clinically important, but require careful interpretation

  • Real-world evidence studies such as a recent study by Fisher (1) examining the persistence of JAK1/3 inhibitor tofacitinib in patients with RA compared to the persistence of bDMARD of a large, retrospective new user cohort from in a research database, are informative but require cautious interpretation because findings are dependent on a variety of medical and nonmedical influences
  • Real-world data are clinically important, and drug survival with appropriate caveats is a good surrogate for continued efficacy and lack of AE necessitating discontinuation
  • Confirmation from similar studies in large registries from a variety of countries with differing medical systems would help to clarify the picture and advise on drug persistence of any novel therapy

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: JUN2021BS001